Effect of dihydrokainate on the capacity of repair of DNA damage and apoptosis induced by doxorubicin

Mutagenesis

Volumn 28, Issue 3, 2013, Pages 257-261

  Attia, Sabry M ^a,b   Bakheet, Saleh A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Al Azhar University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROKAINIC ACID; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; GLUTATHIONE; GLUTATHIONE DISULFIDE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; GENOTOXICITY; IN VITRO STUDY; LIPID PEROXIDATION; MALE; MICRONUCLEUS TEST; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REDUCTION; TREATMENT DURATION;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; BONE MARROW CELLS; DNA DAMAGE; DNA REPAIR; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOXORUBICIN; HUMANS; KAINIC ACID; MALE; MICE; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MITOSIS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

MUS;

EID: 84876518211     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/ges079     Document Type: Article

References (27)

1. Konishi, T. and Dezuki, Y. (1992) Biochemical modulation. CRC Crit. Rev., 1, 88-97.
2. Kubota, Y., Hosaka, M., Fukushima, S. and Kondo, I. (1993) Prophylactic oral UFT therapy for superficial bladder cancer. Cancer, 71, 1842-1845.
3. Ichinose, Y., Takanashi, N., Yano, T., Asoh, H., Yokoyama, H., Tayama, K., Hara, N. and Ohta, M. (1995) A phase II trial of oral tegafur and uracil plus cisplatin in patients with inoperable nonsmall cell lung cancer. Cancer, 75, 2677-2680.
4. Sadzuka, Y., Yamashita, Y., Sugiyama, T. and Sonobe, T. (2002) Effect of dihydrokainate on the antitumor activity of doxorubicin. Cancer Lett., 179, 157-163.
5. Chabner, B. A., Allegra, C. J., Curt, G. A. and Calabresi, P. (1996) Antineoplastic agents. In Hardman, J. G. and Limbird, L. E. (eds), Goodman and Gilman's-The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, pp. 233-287.
6. Pai, V. B. and Nahata, M. C. (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf., 22, 263-302.
7. Theodore, C., Bayle, C., Bernheim, A. and Wibault, P. (2002) Secondary leukaemia after treating advanced bladder cancer with methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and radiotherapy. BJU Int., 90, 470-471.
8. Attia, S. M. (2008) Mutagenicity of some topoisomerase II-interactive agents. S. P. J., 17, 1-24.
9. Gewirtz, D. A. (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol., 57, 727-741.
10. Attia, S. M. (2011) Comparative aneugenicity of doxorubicin and its derivative idarubicin using fluorescence in situ hybridization techniques. Mutat. Res., 715, 79-87.
11. Au, W. W. and Hsu, T. C. (1980) The genotoxic effects of adriamycin in somatic and germinal cells of the mouse. Mutat. Res., 79, 351-361.
12. Adler, I. D. (1984) Cytogenetic tests in mammals. In Venitt, S. and Parry, J. M. (eds), Mutagenicity Testing-a Practical Approach. IRI Press, Oxford, pp. 275-306.
13. Attia, S. M., Badary, O. A., Hamada, F. M., De Angelis, M. H. and Adler, I. D. (2005) Orthovanadate increased the frequency of aneuploid mouse sperm without micronucleus induction in mouse bone marrow erythrocytes at the same dose level. Mutat. Res., 583, 158-167.
14. Attia, S. M., Al-Bakheet, S. A. and Al-Rasheed, N. M. (2010) Proanthocyanidins produce significant attenuation of doxorubicin-induced mutagenicity via suppression of oxidative stress. Oxid. Med. Cell. Longev., 3, 404-413.
15. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F. and Riccardi, C. (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods, 139, 271-279.
16. Attia, S. M. (2010) The impact of quercetin on cisplatin-induced clastogenesis and apoptosis in murine marrow cells. Mutagenesis, 25, 281-288.
17. Bakheet, S. A., Attia, S. M., Al-Rasheed, N. M., et al. (2011) Salubrious effects of dexrazoxane against teniposide-induced DNA damage and programmed cell death in murine marrow cells. Mutagenesis, 26, 533-543.
18. Ohkawa, H., Ohishi, N. and Yagi, K. (1979) Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem., 95, 351-358.
19. Ellman, G. L. (1959) Tissue sulfhydryl groups. Arch. Biochem. Biophys., 82, 70-77.
20. Anderson, M. E. (1985) Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol., 113, 548-555.
21. Attia, S. M. (2012) Dominant lethal mutations of topoisomerase II inhibitors etoposide and merbarone in male mice: a mechanistic study. Arch. Toxicol., 86, 725-731.
22. Bonassi, S., Znaor, A., Ceppi, M. et al. (2007) An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis, 28, 625-631.
23. Ravi, D. and Das, K. C. (2004) Redox-cycling of anthracyclines by thioredoxin system: increased superoxide generation and DNA damage. Cancer Chemother. Pharmacol., 54, 449-458.
24. Acharya, A., Das, I., Chandhok, D. and Saha, T. (2010) Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid. Med. Cell. Longev., 3, 23-34.
25. Attia, S. M. (2010) Deleterious effects of reactive metabolites:. Oxid. Med. Cell. Longev., 3, 238-253.
26. Sugiyama, T. and Sadzuka, Y. (2004) Theanine, a specific glutamate derivative in green tea, reduces the adverse reactions of doxorubicin by changing the glutathione level. Cancer Lett., 212, 177-184.
27. Sadzuka, Y., Yamashita, Y. and Sonobe, T. (2002) Effects of glutamate transporter inhibitors on the antitumor activity of doxorubicin. Clin. Cancer Res., 8, 3943-3947.